Tech Company Financing Transactions

Actym Therapeutics Funding Round

On 10/18/2023, Actym Therapeutics landed $59.5 million in Series A financing from Boehringer Ingelheim Venture Fund, Illumina Ventures and GKCC LLC.

Transaction Overview

Company Name
Actym Therapeutics
Announced On
10/18/2023
Transaction Type
Venture Equity
Amount
$59,500,000
Round
Series A
Investors

Boehringer Ingelheim Venture Fund (Lead Investor) (Kanad Das)

Illumina Ventures (Lead Investor) (Alexis Ji)

GKCC LLC

JLo Ventures

Panacea Venture

Proceeds Purpose
The company intends to use the funds to support entry into a Phase 1 clinical trial. This trial is designed to achieve proof of mechanism for ACTM-838, demonstrating its ability to selectively enrich in tumors, deliver payload combinations there, and positively re-activate the immuno-compromised TME. In addition, the trial is designed to assess the dose selection, safety, efficacy and pharmacokinetics of ACTM-838.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
626 Bancroft Way A
Berkeley, CA 94710
USA
Phone
Undisclosed
Website
www.actymthera.com
Email Address
[email protected]
Overview
Actym Therapeutics is a cutting-edge biotech focused on the discovery and development of novel immuno-oncology therapies.
Profile
Actym Therapeutics LinkedIn Company Profile
Social Media
Actym Therapeutics Company Twitter Account
Company News
Actym Therapeutics News
Facebook
Actym Therapeutics on Facebook
YouTube
Actym Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Christopher Thanos
  Christopher Thanos LinkedIn Profile  Christopher Thanos Twitter Account  Christopher Thanos News  Christopher Thanos on Facebook
VP - Operations
Sheriese Rush
  Sheriese Rush LinkedIn Profile  Sheriese Rush Twitter Account  Sheriese Rush News  Sheriese Rush on Facebook
VP - R & D
Laura Glickman
  Laura Glickman LinkedIn Profile  Laura Glickman Twitter Account  Laura Glickman News  Laura Glickman on Facebook

 

 

Browse more venture capital transactions:

Prev: 10/18/2023: Darwinium venture capital transaction
Next: 10/18/2023: Hivebrite venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.